Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner. Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.
Blinder M.A., Biochemistry 27:752-759(1988).
Herzog R., Biochemistry 30:1350-1357(1991).
Collins J.E., Genome Biol. 5:RESEARCH84.1-RESEARCH84.11(2004).